P. Rachieru (Praticien attaché) , A. Schmidt (Assistante hospitalo-universitaire) , I. Pellier (Praticien hospitalier) , A. Godon (Assistant hospitalo-universitaire) , V. Daniel (Pharmacien hospitalier) , X. Rialland (Praticien hospitalier) , M. Hunault-Berger (Professeur des Universités, Praticien hospitalier) , N. Ifrah (Professeur des Universités, praticien hospitalier, chef de service)
{"title":"Utilisation thérapeutique des immunoglobulines polyvalentes en hématologie","authors":"P. Rachieru (Praticien attaché) , A. Schmidt (Assistante hospitalo-universitaire) , I. Pellier (Praticien hospitalier) , A. Godon (Assistant hospitalo-universitaire) , V. Daniel (Pharmacien hospitalier) , X. Rialland (Praticien hospitalier) , M. Hunault-Berger (Professeur des Universités, Praticien hospitalier) , N. Ifrah (Professeur des Universités, praticien hospitalier, chef de service)","doi":"10.1016/j.emch.2004.08.003","DOIUrl":null,"url":null,"abstract":"<div><p>The efficacy and the safety of intravenous immunoglobulins (IVIG) have been attentively explored since 1970. Their mechanisms of action involve the Fc-receptor blockade, the neutralization of microbial toxins, and the modulation of cytokine production. Their indications depend both on their replacement and immuno-modulation abilities. They include primary antibody deficiencies, secondary hypogammaglobulinemic states with serious repetitive infections, and autoimmune disorders such as the immune thrombocytopenic purpura, whereas IVIG are no more systematically used in sibling hematopoietic stem cell transplantation. Despite major precautions in the manufacturing process, there is still a possible transmission of hitherto unrecognized or recognized infective agents for blood-derived preparations. This emphasizes the need of excellent indications for these expensive products.</p></div>","PeriodicalId":100425,"journal":{"name":"EMC - Hématologie","volume":"1 4","pages":"Pages 150-163"},"PeriodicalIF":0.0000,"publicationDate":"2004-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emch.2004.08.003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Hématologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1638621304000175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The efficacy and the safety of intravenous immunoglobulins (IVIG) have been attentively explored since 1970. Their mechanisms of action involve the Fc-receptor blockade, the neutralization of microbial toxins, and the modulation of cytokine production. Their indications depend both on their replacement and immuno-modulation abilities. They include primary antibody deficiencies, secondary hypogammaglobulinemic states with serious repetitive infections, and autoimmune disorders such as the immune thrombocytopenic purpura, whereas IVIG are no more systematically used in sibling hematopoietic stem cell transplantation. Despite major precautions in the manufacturing process, there is still a possible transmission of hitherto unrecognized or recognized infective agents for blood-derived preparations. This emphasizes the need of excellent indications for these expensive products.